Latest Market Access News

Medical Developments International (MVP) reports positive operating cash flow in H2 FY25, driven by strong Penthrox sales and strategic distribution shifts in Europe. The company eyes further growth amid regulatory progress and efficiency gains.

Comet Ridge Limited has made significant progress in its Mahalo Gas Hub development, advancing engineering design, certifying substantial new gas reserves, and securing extended financing to support a Final Investment Decision.

Orange Minerals NL has begun trading on the U.S. OTCQB Venture Market, enhancing its visibility and liquidity among North American investors while progressing its strategic acquisition of a promising gold project in Ghana.

Control Bionics capped a record FY25 with 15% revenue growth, driven by US market gains and expanding NeuroNode and NeuroStrip technologies. The company also achieved a US profitability milestone and is close to finalizing key distribution partnerships.

Osteopore Limited has posted a record AUD 835K revenue in Q2 CY25, driven by strong APAC sales and new European market access following EU MDR clearance. The company also advances clinical trials and refreshes key distribution channels.

Volt Resources reports robust progress on its Alabama Graphite Refinery scoping study, strategic partnerships in Tanzania, and resilient production in Ukraine, positioning itself strongly amid evolving graphite market dynamics.

Cynata Therapeutics is advancing three pivotal clinical trials targeting acute Graft versus Host Disease, osteoarthritis, and kidney transplantation, with major results expected through early 2026. The company maintains a solid cash position supporting its clinical pipeline and strategic growth.

Critica Limited reports significant progress on its Jupiter Rare Earths Project, unveiling a 95% mass reduction in beneficiation testwork and appointing a new CEO to drive development.

Netlinkz Limited reported $979,000 in quarterly receipts and a landmark $1 million VSN license sale in the Philippines, while advancing significant cost reductions and debt restructuring efforts.

BCAL Diagnostics has reported strong early commercial uptake of its BREASTEST plus non-invasive breast cancer diagnostic test, alongside a new partnership with Cancer Care Associates to expand market reach.

Sarytogan Graphite Limited reports softer ore than expected, improved graphite concentrate grades above 90%, and gains European Union strategic project status, advancing its Definitive Feasibility Study on track for mid-2026 completion.

LTR Pharma has initiated commercial distribution of its nasal spray SPONTAN through Australia's Symbion pharmacy network and is advancing ROXUS development for a US launch in early 2026, while expanding its pipeline with a new intranasal treatment for swallowing disorders.